How We Create Value
Take advantage of our successful expertise at commercialising novel therapies
Sunovion discovers and develops and commercialises novel therapies, working with those with early stage CNS compounds to negotiate and map out a deal that benefits all parties and clarifies activities to develop therapies for trials and commercialisation. Our partners can benefit from the significant development and clinical trials management experience at Sunovion to realise the full development and commercial potential of new and innovative therapies.
Sunovion Pharmaceuticals Europe has the infrastructure in place to develop and commercialise a portfolio of products across Europe. An aggressive in-licensing programme will support this strategy.
Sunovion Pharmaceuticals Europe completed its first partnership agreement with NewBridge in 2016, for the distribution of lurasidone in the Gulf Cooperation Council (GCC) Region.The GCC is composed of Saudi Arabia, Kuwait, the United Arab Emirates, Qatar, Bahrain, and Oman.
Under this exclusive agreement, NewBridge will work closely with Sunovion Pharmaceuticals Europe to seek Marketing Authorisations for lurasidone for the treatment of schizophrenia in adults aged 18 years and over in the GCC Region. Upon receiving a successful Marketing Authorisation, NewBridge will then take responsibility for the distribution, sales and promotion of lurasidone across the Region.
Sunovion Europe announced a partnership with Angelini in November 2017. In this partnership agreement the company has granted exclusive commercialisation rights for lurasidone for the treatment of schizophrenia in adults in 29 European countries and Turkey. Furthermore Sunovion Europe has transferred the marketing authorisation for lurasidone in Europe to Angelini. Angelini launched lurasidone in Italy in November 2017. In partnership arrangements like this, Sunovion Europe continues to play an active role in leading, supporting and providing oversight to the commercialisation in line with an aligned global strategy.